Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)

SPRUCE BIOSCIENCES, INC.

Net loss of $12.3M ($8.94 per share) for Q1 2026; R&D expenses $7.6M, G&A $4.4M.
Cash $54.1M at March 31, 2026; preliminary cash $107.3M at April 30, 2026; runway into H2 2027.
Closed $69.0M diluted public offering in April 2026; secured up to $50M term loan from Avenue Capital (Tranche 1: $15M funded).
BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; long-term data showed durable HS reduction and cognitive stabilization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. reported preliminary financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: preliminary results

Exact text from the filing

On May 13, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates.

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-220648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.